Genomic and transcriptomic analyses in tumors of patients with GBM have shown that the presence of PTEN mutations and higher macrophage abundance are associated with the lack of response to anti-PD1 therapy (28), suggesting that TAMs might contribute to the development of anti-PD1 therapy resistance in PTEN-deficient GBM. Here, PTEN is linked to glioblastoma.